NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline
July 11 2024 - 1:00AM
UK Regulatory
NMD Pharma adds new capabilities with several senior recruits to
support its growing business and pipeline
NMD Pharma adds new capabilities with
several senior recruits to support its growing business and
pipeline
Aarhus, Denmark, 11 July 2024 –
NMD Pharma A/S, a clinical-stage biotech company dedicated to
developing novel and improved treatments for patients living with
severe neuromuscular diseases, today announces that it has hired
three senior recruits to its management team to support its growing
business and pipeline. Peter Kasten will begin as Vice President
Finance in August, Cecilia Sparr Eskilsson as Vice President
Project Management in August and Maja B. Nielsen as People &
Culture Director in September.
Mr. Kasten has over 15 years of experience in
financial operations. Most recently, he was at Danske Fragtmænd, a
Danish transport and logistics business, for several years in
different roles of rising seniority. Prior roles include as
Manager, Advisory Services – Finance and Performance Management at
EY (Ernst & Young) and, notably, 10 years in roles of
increasing responsibility at Novo Nordisk, where his work included
projects to establish research centres in the USA and Denmark
relating to its obesity programs.
Dr. Eskilsson is an accomplished scientist with
over 20 years’ expertise in pharmaceutical drug development at
AstraZeneca and LEO Pharma, with extensive experience in leading
global scientific and strategic projects through clinical
development phases. She will build out the company’s project
management organization.
Ms. Nielsen has been leading global Human
Resources departments in various companies since 2007. She joins
from ENABL, the renewable wind energy company, where she is VP of
Global HR. She brings extensive experience in the development of HR
strategies, performance processes and training and development
policies with companies employing personnel across the globe.
Thomas Holm Pedersen, Co-founder and
Chief Executive Officer of NMD
Pharma,
said: “Over the last year our
business has grown and matured, and we will have three Phase 2
clinical trials initiated and recruiting in North America and
Europe by the end of the year. These high-quality additions to our
management team, together with some other key senior hires, bring a
wealth of knowledge and experience to propel our business forward
with timely execution of a growing pipeline and portfolio of
projects. I look forward to working with Peter, Cecilia, and
Maja.”
NMD Pharma is developing first-in-class,
muscle-targeted small molecule inhibitor of the skeletal muscle
specific ClC-1 chloride ion channel. Three open Investigational New
Drug (IND) studies are progressing for lead development candidate
NMD670, including a Phase 2 clinical study in spinal muscular
atrophy (SMA) (NCT05794139), a Phase 2b study in generalized
myasthenia gravis (gMG) (NCT06414954) and IND clearance to begin a
Phase 2 study in Charcot-Marie-Tooth disease (CMT)
(NCT06482437).
Patients interested in learning more about any
of these trials are encouraged to read the information on currently
active investigational sites which can be found on each on
clinicaltrials.gov webpage referenced above or to contact a member
of our medical team via email at contact@nmdpharma.com.
-END-
Contacts
NMD Pharma A/S
Daniel Brennan, SVP Corporate and Commercial Strategy
E-mail: contact@nmdpharma.com
ICR Consilium
Mary-Jane Elliott / Ashley Tapp / Lindsey Neville
E-mail: NMDPharma@consilium-comms.com
Tel: +44 (0)20 3709 5700
About NMD Pharma
NMD Pharma A/S is a clinical-stage biotech company developing a
first-in-class platform of small molecule therapies selectively and
directly targeting the skeletal muscle chloride ion channel (ClC-1)
for the treatment of severe neuromuscular disorders. The Company
was founded on more than 15 years of muscle physiology research
with a focus on regulation of skeletal muscle excitability under
physical activity. NMD Pharma has built a world-leading muscle
electrophysiology platform leveraging the in-depth know-how of
muscle physiology and muscular disorders, small molecule
modulators, enabling technologies and tools as well as in
vivo pharmacology models for discovering and developing
proprietary modulators of neuromuscular function. The Company has
built significant clinical and development expertise as its
programmes have progressed through the clinic. NMD Pharma has
raised ~€155 million from investors including Novo Holdings,
Lundbeckfonden BioCapital, INKEF Capital, Roche Venture Fund, and
Jeito Capital. Find out more about us online at
http://www.nmdpharma.com.
About NMD670
NMD670 is a first-in-class, muscle-targeted small molecule
inhibitor of the skeletal muscle specific ClC-1 chloride ion
channel. It is NMD Pharma’s lead development program which is being
evaluated in 3 Phase 2 clinical studies in neuromuscular diseases.
NMD Pharma has demonstrated that CIC-1 inhibition enhances skeletal
muscle activation and improves skeletal muscle function. This novel
treatment approach has demonstrated compelling preclinical data and
clinical results in myasthenia gravis, spinal muscular atrophy,
Charcot-Marie-Tooth disease and a range of other neuromuscular
disorders. NMD670 has also been granted orphan-drug designation by
the U.S. FDA for treatment of generalised myasthenia gravis (gMG).
In March 2024 a comprehensive data package on NMD670 was published
in the peer-reviewed journal Science Translational
Medicine which generated significant interest including a
research highlight commentary review in Nature Reviews Drug
Discovery.